Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Felix B who wrote (2446)	6/16/2018 12:42:49 PM
From: Miljenko Zuanic	Read Replies (1) of 3559

To stop development of the Arcalyst (IL-1beta trap) ...was a good decision, as competing Ilaris (hAbs against IL-1beta) was better and safer drug. At the time of the collaboration between REGN and NVS, REGN got royalty on Ilaris sale. So, IF NVS is successful in marketing Ilaris for new indication (cardio-post stroke, gout, cart prophylaxis,...), REGN may end-up with $150-200 M additional royalty. Not bad at all.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next